Cell Therapy Milestones in 2023

Melissa Carpenter, Ph.D., Chief Scientific Officer, Regenerative Medicine, ElevateBio (Moderator)
Abigail Jenkins, President and CEO, Gamida Cell
Adrian Rawcliffe, CEO, Adaptimmune Therapeutics
Pascal Touchon, President and CEO, Atara Biotherapeutics

[@neilmcmanus3727]

The reduction to the choice of who to treat given the cost, is inherently flawed. A prime example is the glaringly lack of rational cost effectiveness with regard to simple rejuvenation of damaged tissue using umbilical cord derived mesenchymal stem/stromal cells (MSCs) aka pericytes, aka newly termed "medicinal signaling cells".
There is an incongruity in the insurance-pharmaceutical-industry-medical practice interrelated decision making group with the exclusion of applying a cost effective medical therapy such as umbilical cord MSCs for resolution of tissue rejuvination. The resultant exclusion within the US has caused this type of treatment to be only available outside the US.
Myself being a cancer survivor, I am acutely aware of the general tissue damage done by conventional chemotherapy and resultant chronic GVHD.

[@onglizzy8868]

On investors - Watch out for those wolves in sheep clothing - The Big Pharma - surely find some reps in the audience !!